Although there have been case reports indicating that larotrectinib was effective in patients with esophageal cancer with gene alterations including NTRK gene amplification in the absence of NTRK fusion genes [54], the extent to which TRK inhibitors exhibit efficacy against NTRK gene amplification has not been established. Here, NTRK1 is linked to esophageal cancer.